I haven't looked at the literature on the topic of in detail and didn't have time to access your paywalled article but in 30 years of experience testing and treating high LDL I have found the changes induced by statin and ezetimibe therapy are dramatic obvious. There is a significant variation in LDL and apo B that I see in patients both…
I haven't looked at the literature on the topic of in detail and didn't have time to access your paywalled article but in 30 years of experience testing and treating high LDL I have found the changes induced by statin and ezetimibe therapy are dramatic obvious. There is a significant variation in LDL and apo B that I see in patients both on and off treatment. Typically on the order of 10% or so. Often, we can identify lifestyle factors that cause this, sometimes not. It is good to have a few measurements at different points prior to treatment and after to fully understand the effects of drug treatment. In the vast majority of patients, however, on average we see more than 10-15% incremental reductions when adding on ezetimibe onto a statin. I am aiming to goals in secondary prevention or high risk primary prevention that are quite aggressive and with a consistent reduction on repeated measurements below the goal apo B and LDL-C targets.
If you just give meds without verifying achieving target goals, you fail to ascertain problems with patient noncompliance with meds or lifestyle and you don't take into account individual factors (like lipo (a), varying intestinal cholesterol absorption, etc.)
I haven't looked at the literature on the topic of in detail and didn't have time to access your paywalled article but in 30 years of experience testing and treating high LDL I have found the changes induced by statin and ezetimibe therapy are dramatic obvious. There is a significant variation in LDL and apo B that I see in patients both on and off treatment. Typically on the order of 10% or so. Often, we can identify lifestyle factors that cause this, sometimes not. It is good to have a few measurements at different points prior to treatment and after to fully understand the effects of drug treatment. In the vast majority of patients, however, on average we see more than 10-15% incremental reductions when adding on ezetimibe onto a statin. I am aiming to goals in secondary prevention or high risk primary prevention that are quite aggressive and with a consistent reduction on repeated measurements below the goal apo B and LDL-C targets.
If you just give meds without verifying achieving target goals, you fail to ascertain problems with patient noncompliance with meds or lifestyle and you don't take into account individual factors (like lipo (a), varying intestinal cholesterol absorption, etc.)